The impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients (pts) with transitional cell carcinoma (TCC) of the bladder.

被引：0
|
作者：
Dash, A [1 ]
Koppie, T [1 ]
Vora, K [1 ]
Bochner, B [1 ]
Galsky, MD [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：399S / 399S
页数：1
相关论文
共 50 条
  • [21] Predictors of outcome in bladder transitional cell carcinoma (TCC) treated by intravesical chemotherapy.
    White, RD
    Deitch, AD
    Daneshmand, S
    Blumenstein, BB
    [J]. JOURNAL OF UROLOGY, 1998, 159 (05): : 145 - 145
  • [22] SYSTEMIC CISPLATIN-BASED CHEMOTHERAPY IN THE TREATMENT OF ADVANCED BLADDER-CARCINOMA
    BOCCONGIBOD, L
    GUINET, F
    CRESSEYKANOUI, C
    DEBRE, B
    STEG, A
    [J]. ANNALES D UROLOGIE, 1985, 19 (04) : 239 - 243
  • [23] Cisplatin-based neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (MIBC) in patients (pts) with impaired renal function.
    Koshkin, Vadim S.
    Barata, Pedro C.
    Zahoor, Haris
    Rybicki, Lisa A.
    Almassi, Nima
    Redden, Alicia M.
    Fergany, Amr Farouk
    Kaouk, Jihad
    Haber, Georges-Pascal
    Stephenson, Andrew J.
    Martin, Allison
    Allman, Kimberly D.
    Beach, Jennifer
    Ornstein, Moshe Chaim
    Gilligan, Timothy D.
    Garcia, Jorge A.
    Rini, Brian I.
    Grivas, Petros
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [24] Intra vesical gemcitabine (G) single agent as adjuvant chemotherapy in superficial transitional cell carcinoma (TCC) of the bladder: Final results
    Bounedjar, A.
    Ferhat, R.
    Smaili, F.
    Bouzid, K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [25] Impact of the chronic kidney disease epidemiology collaboration (CKD-EPI) equation for estimating renal function on eligibility for cisplatin-based chemotherapy in patients with bladder cancer.
    Tsao, C.
    Seng, S. M.
    Grossman, S.
    Oh, W. K.
    Galsky, M. D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [26] Formulas calculating creatinine clearance are inadequate for determining eligibility for cisplatin-based chemotherapy in bladder cancer
    Raj, Ganesh V.
    Iasonos, Alexia
    Herr, Harry
    Donat, Sherri Machele
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (19) : 3095 - 3100
  • [27] Clinical significance of HER-2/neu amplification and expression in transitional cell carcinoma (TCC) of the urinary bladder.
    Graber, MW
    Abrahams, HM
    Sheehan, CE
    Fisher, HAG
    Kaufman, RP
    Ross, JS
    [J]. LABORATORY INVESTIGATION, 1999, 79 (01) : 96A - 96A
  • [28] INTRAARTERIAL CHEMOTHERAPY AS AN ADJUVANT TO SURGERY IN TRANSITIONAL CELL-CARCINOMA OF THE BLADDER
    MAATMAN, TJ
    MONTIE, JE
    BUKOWSKI, RM
    RISIUS, B
    GEISINGER, M
    [J]. JOURNAL OF UROLOGY, 1986, 135 (02): : 256 - 260
  • [29] Is Carcinoma In Situ (CIS), a contra-indication for neoadjuvant chemotherapy for Transitional Cell Carcinoma (TCC) of the bladder?
    Ahmad, M. S.
    Cresswell, J.
    Eronini, N. U.
    Whiteway, J. E.
    Thorpe, A. C.
    [J]. EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (08) : 582 - 583
  • [30] THE COMBINATION OF CISPLATIN-BASED CHEMOTHERAPY AND RADIATION IN THE TREATMENT OF MUSCLE-INVADING TRANSITIONAL-CELL CANCER OF THE BLADDER
    ZIETMAN, AL
    SHIPLEY, WU
    KAUFMAN, DS
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1993, 27 (01): : 161 - 170
12345